<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01031030</url>
  </required_header>
  <id_info>
    <org_study_id>IRST-IBIS-03</org_study_id>
    <secondary_id>CDR0000661068</secondary_id>
    <nct_id>NCT01031030</nct_id>
  </id_info>
  <brief_title>Cyclophosphamide, Methotrexate, and Fluorouracil, With or Without Epirubicin Hydrochloride, in Treating Women Who Have Undergone Surgery for Breast Cancer (Group III Closed to New Patients as of 12/7/2009)</brief_title>
  <official_title>Adjuvant Treatment of Biologically Aggressive Breast Cancer (N-,N+1,3): Controlled Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, methotrexate, fluorouracil,&#xD;
      and epirubicin hydrochloride, work in different ways to stop the growth of tumor cells,&#xD;
      either by killing the cells or by stopping them from dividing. It is not yet known whether&#xD;
      giving cyclophosphamide together with methotrexate and fluorouracil before, after, or without&#xD;
      epirubicin hydrochloride is more effective in treating patients with breast cancer that can&#xD;
      be removed by surgery.&#xD;
&#xD;
      PURPOSE: This randomized phase III trial is comparing three regimens of cyclophosphamide&#xD;
      given together with methotrexate and fluorouracil, with or without epirubicin hydrochloride,&#xD;
      to see how well it works in treating women who have undergone surgery for breast cancer.&#xD;
      (Group III was closed to new patients as of 12/7/2009.)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To determine the impact of adjuvant chemotherapy comprising epirubicin hydrochloride&#xD;
           followed by cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide,&#xD;
           methotrexate, and fluorouracil followed by epirubicin hydrochloride versus&#xD;
           cyclophosphamide, methotrexate, and fluorouracil on overall survival of patients with&#xD;
           biologically aggressive, resectable, node-negative or node-positive breast cancer.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To assess the disease-free survival and patterns of relapse in these patients.&#xD;
&#xD;
        -  To assess the tolerance to and toxicity of treatment in these patients.&#xD;
&#xD;
        -  To determine the quality of life of these patients.&#xD;
&#xD;
        -  To verify the effectiveness of these treatments in different subgroups of patients.&#xD;
&#xD;
        -  To collect, retrospectively, information on the expression of tumor suppressor gene p53,&#xD;
           oncogene c-erbB-2, and bcl-2 protein involved in apoptosis. (exploratory)&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified according to center, lymph node&#xD;
      status (N0 vs N1-3), and estrogen receptor status (negative vs positive). Patients are&#xD;
      randomized to 1 of 3 treatment arms.&#xD;
&#xD;
        -  Arm I: Beginning 4-6 weeks following surgery, patients receive epirubicin hydrochloride&#xD;
           IV on day 1. Treatment repeats every 3 weeks for 4 courses. Patients then receive&#xD;
           cyclophosphamide IV, methotrexate IV, and fluorouracil IV on days 1-8. Treatment repeats&#xD;
           every 4 weeks for 4 courses.&#xD;
&#xD;
        -  Arm II: Beginning 4-6 weeks following surgery, patients receive cyclophosphamide IV,&#xD;
           methotrexate IV, and fluorouracil IV on days 1-8. Treatment repeats every 4 weeks for 4&#xD;
           courses. Patients then receive epirubicin hydrochloride IV on day 1. Treatment repeats&#xD;
           every 3 weeks for 4 courses.&#xD;
&#xD;
        -  Arm III (closed to accrual as of 12/7/2009): Beginning 4-6 weeks following surgery,&#xD;
           patients receive cyclophosphamide IV, methotrexate IV, and fluorouracil IV on days 1-8.&#xD;
           Treatment repeats every 4 weeks for 6 courses.&#xD;
&#xD;
      Patients with estrogen receptor-positive disease receive tamoxifen daily for 5 years after&#xD;
      completing chemotherapy.&#xD;
&#xD;
      After completion of study therapy, patients are followed every 3 months for 1 year, every 6&#xD;
      months for 4 years, and then annually for 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 1997</start_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy in subgroups of patients</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epirubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed breast cancer&#xD;
&#xD;
               -  Underwent radical mastectomy, guadrantectomy, or tumorectomy with axillary node&#xD;
                  dissection within the past 4-6 weeks&#xD;
&#xD;
               -  Biologically aggressive disease&#xD;
&#xD;
               -  At least 10 lymph nodes removed&#xD;
&#xD;
                    -  Node-negative (&gt; 1 cm, or &gt; 2 cm if histology is favorable, esp. tubular&#xD;
                       carcinoma and/or prevalent intraductal component &gt; 50%) tumors OR&#xD;
                       node-positive (1-3) tumors, meeting the following criteria:&#xD;
&#xD;
                         -  High thymidine-labeling index (&gt; 3%)&#xD;
&#xD;
                         -  Poorly differentiated tumor (grade III)&#xD;
&#xD;
                         -  High S-phase fraction (&gt; 10% by flow cytometry)&#xD;
&#xD;
                         -  High Ki67/MIB1 expression (&lt; 20%)&#xD;
&#xD;
          -  No bilateral breast cancer&#xD;
&#xD;
          -  No T4a, inoperable T4b, T4c, or T4d disease&#xD;
&#xD;
          -  Any estrogen receptor status (positive, negative, unknown)&#xD;
&#xD;
          -  No distant metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Any menopause status&#xD;
&#xD;
          -  WBC ≥ 3,500/mL&#xD;
&#xD;
          -  ANC ≥ 1,500/mL&#xD;
&#xD;
          -  Platelet count ≥ 120,000/mL&#xD;
&#xD;
          -  AST and ALT ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Creatinine ≤ 1.5 mg/mL&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times ULN&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Geographically accessible for follow-up&#xD;
&#xD;
          -  No prior breast cancer and/or other cancer except for carcinoma in situ of the cervix&#xD;
             or basal cell skin cancer treated with radical intent&#xD;
&#xD;
          -  No significant alterations in cardiovascular function&#xD;
&#xD;
          -  No serious psychiatric disorders&#xD;
&#xD;
          -  No impaired renal or liver function&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dino Amadori, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Morgagni-Pierantoni Ospedale</affiliation>
  </overall_official>
  <verification_date>December 2009</verification_date>
  <study_first_submitted>December 11, 2009</study_first_submitted>
  <study_first_submitted_qc>December 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2009</study_first_posted>
  <last_update_submitted>August 1, 2013</last_update_submitted>
  <last_update_submitted_qc>August 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 2, 2013</last_update_posted>
  <keyword>stage I breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

